Stocks & Investing
Stocks and InvestingStocks and Investing 
Mon, October 19, 2009
Sun, October 18, 2009
Sat, October 17, 2009
Fri, October 16, 2009
Naked Short Web Site Announces HPCO, EXK, SOFN, BVTI, TPI Have Been Removed From Threshold Lists Today
October 16, 2009 /M2 PRESSWIRE/ BUYINS.NET, www.buyins.net, announced today that these select companies have been removed from the NASDAQ, AMEX and NYSE naked short threshold lists. Hallador Petroleum (OTCBB: HPCO), Endeavour Silver (AMEX: EXK), Softnet Technology (OTC: SOFN), Biovest International (OTC: BVTI) and Tianyin Pharmaceutical (AMEX: TPI). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
Hallador Petroleum Company (OTCBB: HPCO), through its subsidiary, Sunrise Coal, LLC, engages in the production and sale of coal in the United States. The company owns a 80% interest in the Carlisle coal mine located in western Indiana. It also holds a 45% interest in Savoy Energy, L.P., an oil and gas company that has operations in Michigan. The company sells its coal to producers of electric power. Hallador Petroleum Company was founded in 1949 and is based in Denver, Colorado. There is no longer a failure to deliver in shares of HPCO.
Endeavour Silver Corp. (AMEX: EXK), a mining company, engages in the evaluation, acquisition, exploration, development, and exploitation of precious metal properties, primarily silver in Mexico. It produces silver and gold from its underground mines at the Guanacevi mines project in Durango, Mexico; and the Guanajuato mines project, located in the state of Guanajuato, Mexico. The company was formerly known as Endeavour Gold Corp. and changed its name to Endeavour Silver Corp. in September 2004. Endeavour Silver Corp. was founded in 1981 and is based in Vancouver, Canada. There is no longer a failure to deliver in shares of EXK.
SoftNet Technology Corporation (OTC: SOFN), through its subsidiaries, offers information technology (IT) consulting services and solutions in the United States. It provides technology infrastructure services primarily in information security, information storage, networking, network management, systems integration, and application delivery solutions. The company also offers a range of consulting and recruiting services to plan, deploy, and manage IT services and infrastructures. It markets its services to commercial enterprises, telecommunication service providers, and governmental agencies and organizations. The company is based in Iselin, New Jersey. There is no longer a failure to deliver in shares of SOFN.
Biovest International, Inc. (OTC: BTVI), a biotechnology company, develops therapeutic anti-cancer vaccine for the treatment of low-grade Follicular Lymphoma in the United States. It develops BiovaxID, a Phase III clinical trial product, which is an injectable patient-specific vaccine to treat the follicular form of non-Hodgkina�s lymphoma. The company develops, manufactures, and markets cell culture systems, equipment, and consumable parts to pharmaceutical, diagnostic, and biotechnology companies, as well as to research institutions worldwide. Biovest International also produces mammalian and insect cells, monoclonal antibodies, recombinant and secreted proteins, and other cell culture products using hollow fiber perfusion. It is also developing an automated cell culture instrument, AutovaxID that enables production of personalized cell-based treatments. In addition, the company sells hollow fiber bioreactors, cultureware, tubing sets, and other disposable products and supplies. Further, Biovest International engages in the production and contract manufacture of biologic drugs and cell production for research institutions. Its customers include biopharmaceutical and biotech companies, medical schools, universities, research facilities, hospitals, and public and private laboratories. The company was incorporated in 1981 as Endotronics, Inc. and changed its name to Cellex Biosciences, Inc. in 1993. Further, it changed its name to Biovest International, Inc. in 2001. The company is based in Tampa, Florida. Biovest International, Inc. is a subsidiary of Accentia Biopharmaceuticals, Inc. On November 10, 2008, Biovest International Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Middle District of Florida, Tampa, in joint administration with Accentia Biopharmaceuticals, Inc. There is no longer a failure to deliver in shares of BVTI.
Tianyin Pharmaceutical Co., Inc. (AMEX: TPI) engages in the development, manufacture, marketing, and sale of modernized traditional Chinese medicines and other pharmaceuticals in the Peoplea�s Republic of China. The companya�s products are intended to address various medical needs in the therapeutic areas spanning internal medicines, gynecology, hepatology, otolaryngology, urology, neurology, gastroenterology, orthopedics, dermatology, and pediatrics. It manufactures a portfolio of 39 modernized traditional Chinese medicines and pharmaceuticals, and has a pipeline of 17 products, which are pending regulatory approvals with the China State Food and Drug Administration. The company was founded in 1994 and is based in Chengdu, the Peoplea�s Republic of China. There is no longer a failure to deliver in shares of TPI.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.com/squeezetrigger.pdf . The SqueezeTrigger database of nearly 2,650,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha�s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Occasionally companies mentioned in this report pay a $995.00 monthly data fee to Buyins.net for one month of research data. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
Contact: Thomas Ronk / CEO / www.BUYINS.net / (800) 715-9999 / tom@buyins.net